Gram-positive cocci multiresistant to antibiotics: Activity of linezolid;Les coques à gram-positif multirésistants aux antibiotiques: Intérêt du linézolide

Medecine et Maladies Infectieuses

Volumn 32, Issue 9, 2002, Pages 449-459

  Leclercq, R ^a  

^a CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

Enterococcus faecium; Linezolid; Staphylococcus aureus

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; CEFOTAXIME; CEFPIROME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; FOSFOMYCIN; FUSIDIC ACID; GATIFLOXACIN; GENTAMICIN; GLYCOPEPTIDE; LINEZOLID; MACROLIDE; METICILLIN; MOXIFLOXACIN; OFLOXACIN; PENICILLIN DERIVATIVE; PENICILLIN G; PRISTINAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; TEICOPLANIN; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; BACTERIAL INFECTION; BACTERIAL TRANSMISSION; CROSS RESISTANCE; ENTEROCOCCUS FAECIUM; GRAM POSITIVE COCCI; MULTIDRUG RESISTANCE; NONHUMAN; REVIEW; STAPHYLOCOCCUS AUREUS;

EID: 0036751258     PISSN: 0399077X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-077X(02)00412-2     Document Type: Review

References (91)

1. Soussy CJ, Denoyer MC, Duval J, Goldstein F, Guibert JM, Acar JF, et al. Les bactéries «résistantes à tout» existent-elles? Résultats d'une enquête épidémiologique dans trois centres hospitaliers parisiens. Méd Mal Infect 1974;4:341-8.
2. Livermore DM. Quinupristin/dalfopristin and linezolid: where, when, which and whether to use? J Antimicrob Chemother 2000;46:347-50.
3. Rice LB. Emergence of vancomycin-resistant enterococci. Emerg Infect Dis 2001;7:183-7.
4. Rybkine T, Mainardi JL, Sougakoff W, Collatz E, Gutmann L. Penicillin-binding protein 5 sequence alterations in clinical isolates of Enterococcus faecium with different levels of beta-lactam resistance. J Infect Dis 1998;178:159-63.
5. Grayson ML, Eliopoulos GM, Wennersten CB, Ruoff KL, De Girolami PC, Ferraro MJ, et al. Increasing resistance to beta-lactam antibiotics among clinical isolates of Enterococcus faecium: a 22-year review at one institution. Antimicrob Agents Chemother 1991;35:2180-4.
6. Boyce JM, Opal SM, Potter-Bynoe G, LaForge RG, Zervos MJ, Furtado G, et al. Emergence and nosocomial transmission of ampicillin-resistant enterococci. Antimicrob Agents Chemother 1992;36:1032-9.
7. Chirurgi VA, Oster SE, Goldberg AA, McCabe RE. Nosocomial acquisition of beta-lactamase-negative, ampicillin-resistant enterococcus. Arch Intern Med 1992;152:1457-61.
8. Leclercq R, Dutka-Malen S, Brisson-Noel A, Molinas C, Derlot E, Arthur M, et al. Resistance of enterococci to aminoglycosides and glycopeptides. Clin Infect Dis 1992;15:495-501.
9. e Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse. 2000. p. 189 (résumé 282).
10. Leclercq R, Courvalin P. Resistance to glycopeptides in enterococci. Clin Infect Dis 1997;24:545-54.
11. Schouten MA, Hoogkamp-Korstanje JA, Meis JF, Voss A. Prevalence of vancomycin-resistant enterococci in Europe. Eur J Clin Microbiol Infect Dis 2000;19:816-22.
12. National Nosocomial Infections Surveillance. Antimicrobial Resistance ICU surveillance, 1999. www.cdc.gov/ncidod/hip/NNIS.
13. Schouten MA, Voss A, Hoogkamp-Korstanje JA. Antimicrobial susceptibility patterns of enterococci causing infections in Europe. The European VRE Study Group. Antimicrob Agents Chemother 1999;43:2542-6.
14. Andrews J, Ashby J, Jevons G, Marshall T, Lines N, Wise R. A comparison of antimicrobial resistance rates in Gram-positive pathogens isolated in the UK from October 1996 to January 1997 and October 1997 to January 1998. J Antimicrob Chemother 2000;45:285-93.
15. Reacher MH, Shah A, Livermore DM, Wale MC, Graham C, Johnson AP, et al. Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. BMJ 2000;320:213-6.
16. Pangon B, Pina P, Gazagne L, Chauvel M, Godard T, Courvalin P, et al. Antimicrobial susceptibility of 471 enterococcal strains responsible for infections at 101 French hospitals. Collége de Bactériologie, Virologie, Hygiéne des Hôpitaux. Eur J Clin Microbiol Infect Dis 1999;18:836-8.
17. Guérin F, Perrier-Gros-Claude JD, Foissaud V, Masseron T, Thierry J. Entérocoques résistants à la vancomycine en France: haute prévalence dans une population ambulatoire de sujets jeunes. Presse Med 1998;27:1427-9.
18. Wegener HC, Aarestrup FM, Jensen LB, Hammerum AM, Bager F. Use of antimicrobial growth promoters in food animals and Enterococcus faecium resistance to therapeutic antimicrobial drugs in Europe. Emerg Infect Dis 1999;5:329-35.
19. Hoogkamp-Korstanje JA, Roelofs-Willemse J. Comparative in vitro activity of moxifloxacin against Gram-positive clinical isolates. J Antimicrob Chemother 2000;45:31-9.
20. Tankovic J, Mahjoubi F, Courvalin P, Duval J, Leclercq R. Development of fluoroquinolone resistance in Enterococcus faecalis and role of mutations in the DNA gyrase gyrA gene. Antimicrob Agents Chemother 1996;40:2558-61.
21. Tankovic J, Bachoual R, Ouabdesselam S, Boudjadja A, Soussy CJ. In-vitro activity of moxifloxacin against fluoroquinolone-resistant strains of aerobic gram-negative bacilli and Enterococcus faecalis. J Antimicrob Chemother 1999;43(Suppl B):19-23.
22. Grayson ML, Thauvin-Eliopoulos C, Eliopoulos GM, Yao JD, De Angelis DV, Walton L, et al. Failure of trimethoprimsulfamethoxazole therapy in experimental enterococcal endocarditis. Antimicrob Agents Chemother 1990;34:1792-4.
23. Chenoweth CE, Robinson KA, Schaberg DR. Efficacy of ampicillin versus trimethoprim-sulfamethoxazole in a mouse model of lethal enterococcal peritonitis. Antimicrob Agents Chemother 1990;34:1800-2.
24. Boyce JM, Opal SM, Chow JW, Zervos MJ, Potter-Bynoe G, Sherman CB, et al. Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance. J Clin Microbiol 1994;32:1148-53.
25. Carbonne A, pour le Réseau Microbiologie du CCLIN Paris-Nord (hors AP-HP). Surveillance des bactéries multirésistantes à partir du laboratoire. Bulletin du CCLIN paris-Nord 2000;17:4-5.
26. Lelievre H, Lina G, Jones ME, Olive C, Forey F, Roussel-Delvallez M, et al. Emergence and spread in French hospitals of methicillin-resistant Staphylococcus aureus with increasing susceptibility to gentamicin and other antibiotics. J Clin Microbiol 1999;37:3452-7.
27. Lepelletier D, Richet H. Surveillance et contrôle des infections à Staphylococcus aureus résistants à la méticilline dans les hôpitaux français. BEH 2001;6:25-7.
28. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997;40:135-6.
29. Griffith RS. Vancomycin use - an historical review. J Antimicrob Chemother 1984(Suppl D):1-5.
30. Kaatz G, Seo SM, Dorman NJ, Lerner SA. Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis. J Infect Dis 1990;162:103-8.
31. Mainardi JL, Shlaes DM, Goering RV, et al. Decreased teicoplanin susceptibility of methicillin-resistant strains of Staphylococcus aureus. J Infect Dis 1995;171:1646-50.
32. Ferraz V, Duse AG, Kassel M, Black AD, Ito T, Hiramatsu K. Vancomycin-resistant Staphylococcus aureus occurs in South Africa. S Afr Med J 2000;90:1113.
33. Bierbaum G, Fuchs K, Lenz W, Szekat C, Sahl HG. Presence of Staphylococcus aureus with reduced susceptibility to vancomycin in Germany. Eur J Clin Microbiol Infect Dis 1999;18:691-6.
34. Kim MN, Pai CH, Woo JH, Ryu JS, Hiramatsu K. Vancomycin-intermediate Staphylococcus aureus in Korea. J Clin Microbiol 2000;38:3879-81.
35. Ploy MC, Grelaud C, Martin C, de Lumley L, Denis F. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 1998;351:1212.
36. Howe RA, Bowker KE, Walsh TR, Feest TG, MacGowan AP. Vancomycin-resistant Staphylococcus aureus. Lancet 1998;351:602.
37. Trakulsomboon S, Danchaivijitr S, Rongrungruang Y, Dhiraputra C, Susaemgrat W, Ito T, et al. First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand. J Clin Microbiol 2001;39:591-5.
38. Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001;7:327-32.
39. Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med 1999;340:493-501.
40. Rotun SS, McMath V, Schoonmaker DJ, Maupin PS, Tenover FC, Hill BC, et al. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg Infect Dis 1999;5:147-9.
41. Schmitz FJ, Krey A, Geisel R, Verhoef J, Heinz HP, Fluit AC. Susceptibility of 302 methicillin-resistant Staphylococcus aureus isolates from 20 European university hospitals to vancomycin and alternative antistaphylococcal compounds. SENTRY Participants Group. Eur J Clin Microbiol Infect Dis 1999;18:528-30.
42. Cui L, Murakami H, Kuwahara-Arai K, Hanaki H, Hiramatsu K. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob Agents Chemother 2000;44:2276-85.
43. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997;350:1670-3.
44. Chesneau O, Morvan A, Solh NE. Retrospective screening for heterogeneous vancomycin resistance in diverse Staphylococcus aureus clones disseminated in French hospitals. J Antimicrob Chemother 2000;45:887-90.
45. Guérin F, Buu-Hoi A, Mainardi JL, Kac G, Colardelle N, Vaupre S, et al. Outbreak of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in a Parisian hospital. J Clin Microbiol 2000;38:2985-8.
46. Carricajo A, Mallaval F, Fonsale N, Vautrin AC, Aubert G. Recherche des souches de Staphylococcus aureus de sensibilité diminuée aux glycopeptides dans un hôpital universitaire (juin 1999-février 2000). Méd Mal Infect 1999;31:683-4.
47. e Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse. 2000. p. 191 (résuḿ 287).
48. e Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse. 2000. p. 191 (résuḿ 288).
49. Pina P, Marliere C, Vandenesch F, Bedos JP, Etienne J, Allouch PY. An outbreak of Staphylococcus aureus strains with reduced susceptibility to glycopeptides in a French general hospital. Clin Infect Dis 2000;31:1306-8.
50. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995;274:639-44.
51. Schwalbe RS, Stapleton JT, Gilligan PH. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med 1987;316:927-31.
52. Garrett DO, Jochimsen E, Murfitt K, Hill B, McAllister S, Nelson P, et al. The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis. Infect Control Hosp Epidemiol 1999;20:167-70.
53. Doit C, Loukil C, Fitoussi F, Geslin P, Bingen E. Emergence in france of multiple clones of clinical Streptococcus pneumoniae isolates with high-level resistance to amoxicillin. Antimicrob Agents Chemother 1999;43:1480-3.
54. Novak R, Henriques B, Charpentier E, Normark S, Tuomanen E. Emergence of vancomycin tolerance in Streptococcus pneumoniae. Nature 1999;399:590-3.
55. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 1999;29:490-4.
56. Portier H, Kazmierczak A, Lucht F, Tremeaux JC, Chavanet P, Duez JM. Cefotaxime in combination with other antibiotics for the treatment of severe methicillin-resistant staphylococcal infections. Infection 1985;13(Suppl 1):S123-8.
57. Bergeret M, Raymond J. In-vitro bactericidal activity of cefpirome and cefamandole in combination with glycopeptides against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 1999;43:291-4.
58. Rochon-Edouard S, Pestel-Caron M, Lemeland JF, Caron F. In vitro synergistic effects of double and triple combinations of beta-lactams, vancomycin, and netilmicin against methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 2000;44:3055-60.
59. Moellering RC. Quinupristin/dalfopristin: therapeutic potential for vancomycin-resistant enterococcal infections. J Antimicrob Chemother 1999;44(Suppl A):25-30.
60. Pechere JC. Current and future management of infections due to methicillin-resistant staphylococci infections: the role of quinupristin/dalfopristin. J Antimicrob Chemother 1999;44(Suppl A):11-8.
61. Fuchs PC, Barry AL, Brown SD. Bactericidal activity of quinupristin-dalfopristin against Staphylococcus aureus: clindamycin susceptibility as a surrogate indicator. Antimicrob Agents Chemother 2000;44:2880-2.
62. Pavie J, Zarrouk V, Lefort A, Garry, L, Leclercq R, Carbon C, et al. Activity of combination of quinupristin-dalfopristin and vancomycin in vitro and in experimental endocarditis due to Staphylococcus aureus susceptible or resistant to quinupristin. Abstract 1006. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 17-20, 2000.
63. Vouillamoz J, Entenza JM, Feger C, Glauser MP, Moreillon P. Quinupristin-dalfopristin combined with beta-lactams for treatment of experimental endocarditis due to Staphylococcus aureus constitutively resistant to macrolide-lincosamide-streptogramin B antibiotics. Antimicrob Agents Chemother 2000;44:1789-95.
64. Diekema DI, Jones RN. Oxazolidinones: a review, Drugs. (59) 2000:7-16.
65. Clemett D, Markham A. Linezolid. Drugs 2000;59:815-27.
66. Wise R, Andrews JM, Boswell FJ, Ashby JP. The in-vitro activity of linezolid (U-100766) and tentative breakpoints. J Antimicrob Chemother 1998;42:721-8.
67. Rybak MJ, Hershberger E, Moldovan T, Grucz RG. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristindalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 2000;44:1062-6.
68. Bostic GD, Perri MB, Thal LA, Zervos MJ. Comparative in vitro and bactericidal activity of oxazolidinone antibiotics against multidrug-resistant enterococci. Diagn Microbiol Infect Dis 1998;30:109-12.
69. Green SL, Maddox JC, Huttenbach ED. Linezolid and reversible myelosuppression. JAMA 2001;285:1291.
70. Von Eiff C, Peters G. Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci. J Antimicrob Chemother 1999;43:569-73.
71. Cercenado E, Garcia-Garrote F, Bouza E. In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates. J Antimicrob Chemother 2001;47:77-81.
72. Henwood CJ, Livermore DM, Johnson AP, James D, Warner M, Gardiner A. Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group. J Antimicrob Chemother 2000;46:931-40.
73. Johnson AP, Warner M, Livermore DM. Activity of linezolid against multi-resistant gram-positive bacteria from diverse hospitals in the United Kingdom. J Antimicrob Chemother 2000;45:225-30.
74. Noskin GA, Siddiqui F, Stosor V, Hacek D, Peterson LR. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci. Antimicrob Agents Chemother 1999;43:2059-62.
75. e Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse. 2000. p. 180 (résumé 258).
76. Wootton M, Howe RA, Walsh TR, Bennett PM. In-vitro activity of a range of old and new antimicrobials to hetero-vancomycin-intermediate Staphylococcus aureus. Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, Abstract 2313. Washington, DC: American Society for Microbiology; 2000. p. 188.
77. Eliopoulos GM, Wennersten CB, Gold HS, Moellering Jr RC. In vitro activities in new oxazolidinone antimicrobial agents against enterococci. Antimicrob Agents Chemother 1996;40:1745-7.
78. Fines M, Leclercq R. Activity of linezolid against Gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors. J Antimicrob Chemother 2000;45:797-802.
79. Patel R, Rouse MS, Piper KE, Steckelberg JM. Linezolid therapy of vancomycin-resistant Enterococcus faecium experimental endocarditis. Antimicrob Agents Chemother 2001;45:621-3.
80. Dailey CF, Dileto-Fang CL, Buchanan LV, Oramas-Shirey MP, Batts DH, Ford CW, et al. Efficacy of Linezolid in treatment of experimental endocarditis caused by Methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2001;45:2304-8.
81. Rubinstein E, Cammarata S, Oliphant T, Wunderink R, Linezolid. (PNU-100766) versus Vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001;32:402-12.
82. Birmingham MC, Zimmer GS, Flavin SM, Rayner CR, Welch KE, Smith PF, et al. Results of treating bacteremic patients with linezolid in a compassionate use trial for resistant gram-positive infections. Final program and abstracts, 37th Annual meeting of the Infectious Diseases Society of America, Philadelphia, poster 127. Alexandria, VA, 1999: Infectious Diseases Society of America; 1999. p. 62.
83. Noskin GA, Siddiqui F, Stosor V, Kruzynski J, Peterson LR. Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin. Clin Infect Dis 1999;28:689-90.
84. Babcock HM, Ritchie DJ, Christiansen E, Starlin R, Little R, Stanley S. Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid. Clin Infect Dis 2001;32:1373-5.
85. Zeana C, Kubin CJ, Della-Latta P, Hammer SM. Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: case report and review of the literature. Clin Infect Dis 2001;33:477-82.
86. Li Z, Willke RJ, Pinto LA, Rittenhouse BE, Rybak MJ, Pleil AM, et al. Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy 2001;21:263-74.
87. Xiong L, Kloss P, Douthwaite S, Andersen NM, Swaney S, Shinabarger DL, et al. Oxazolidinone resistance mutations in 23S rRNA of Escherichia coli reveal the central region of domain V as the primary site of drug action. J Bacteriol 2000;182:5325-31.
88. Prystowsky J, Siddiqui F, Chosay J, Shinabarger DL, Millichap J, Peterson LR, et al. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob Agents Chemother 2001;45:2154-6.
89. Shinabarger D. Mechanisms of resistance to oxazolidinones. Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, Abstract 1134. Washington, DC: American Society for Microbiology; 2000. p. 534.
90. Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001;357:1179.
91. Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001;358:207-8.